Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Ind-Swift Laboratories Ltd Stock Analysis

Small Cap
Evaluated by 539 users | BSE: 532305 | NSE: INDSWFTLAB |
Pharmaceuticals & Drugs
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. It has been promoted by Ind-Swift Limited in a joint venture with the Punjab State Industrial Development Corporation Limited (PSIDC). The group has established a strong reputation as innovators in the...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Capital Employed 10.31%9.04%-0.57%-0.87%-01.24%1.38%2.27%2.33%2.64%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 1,0201,3211,083941646639675728724752857
Y-o-Y Gr. Rt.-29.5%-18%-13.1%-31.4%-1.1%5.7%7.9%-0.5%3.8%-
Adjusted EPS (Rs.) 25.1122.85-27.76-24.35-20.06-12.17-8.343.06-5.4-5.16-0.74
Y-o-Y Gr. Rt.--9%-221.5%NANANANANA-276.5%NA-
Book Value per Share (Rs.) 141.12157.82125.3792.4966.656.1156.8663.473.5370.8875.48
Adjusted Net Profit 85.986.7-109-99.7-82.2-49.9-37.313.9-25.7-30.5-4
Net Op. Cash Flow (Rs. Cr.) 12.676.4-46.166.399.980.492.771.5-74.6123-
Debt to Cash Flow from Ops 65.2113.25-26.8920.4414.1418.1213.4115.16-14.958.11-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Ind-Swift Laboratories Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -3.3%3.1%3.7%3.8%
Adjusted EPS -183.9%NANANA
Book Value per Share -7.41.37.6-3.6
Share Price 2% 11% -0.7% 42.1%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Equity (%) 16.6512.35-13.01-12.67-12.49-9.01-7.172.59-4.53-4.93-1.01
Operating Profit Margin (%) 16.5413.296.516.2313.7716.715.5717.4117.318.7621.07
Net Profit Margin (%) 8.436.56-10.07-10.6-12.72-7.81-5.531.9-3.54-4.05-0.51
Debt to Equity 1.71.692.523.585.176.324.873.763.182.38-
Working Capital Days 224230318385546531478427428420-
Cash Conversion Cycle 109124194235322314305286278267-
Loading price chart...
Entity Percentage Holding
Promoters 42.00%
Institutions 19.55%
Non-Institutions 38.46%
Pledged *86.8786.8786.8786.8786.8786.8786.8786.8786.8786.87
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Ind-Swift Laboratories Ltd's earnings have grown by 0%, whereas share price has appreciated 11% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Ind-Swift Laboratories Ltd share price has declined -2.6% annually (CAGR) over the past ten years.

Data is not available for this company.

Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. It has been promoted by Ind-Swift Limited in a joint venture with the Punjab State Industrial Development Corporation Limited (PSIDC). The group has established a strong reputation as innovators in the Indian pharmaceutical industry. 

Ind-Swift Laboratories Ltd. went public in 1997 and concentrated on the manufacturing of Active Pharmaceutical Ingredients (API). Its

Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. It has been promoted by Ind-Swift Limited in a joint venture with the Punjab State Industrial Development Corporation Limited (PSIDC). The group has established a strong reputation as innovators in the Indian pharmaceutical industry. 

Ind-Swift Laboratories Ltd. went public in 1997 and concentrated on the manufacturing of Active Pharmaceutical Ingredients (API). Its strength in organic synthetic chemistry resulted in the company emerging as the pioneer for a number of products both in the national and international markets. As the company built up vast skills in the area of research and development, quality systems as well as matters relating to regulatory compliance, it began establishing a presence in the highly regulated markets of the world.

Over a short period of time, Ind-Swift Laboratories Ltd. has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries. Not only are the company's plants built as per USFDA, the company employs current Good Manufacturing Practices (cGMP) also, which are recognised and accepted in the stringent regulated markets. This includes a responsible commitment to the environment.   To leverage its quality commitment, the Company has drawn out a long term strategy of emerging as a powerful force in the regulated markets as drugs worth over US$ 80 billion goes off patent during this decade.

The company's shares are listed on the Bombay, National, Ludhiana and Delhi stock exchanges.

Product range of the company include:

  • Macrolide antibiotics
  • Cardiovascular
  • Anti histamine
  • Anti diabetic
  • Analgesic
  • Aromatase inhibtors
  • Anti depressant
  • Alcohol absistence

MANUFACTURING

Ind-Swift's manufacturing facilities are second to none, and in fact has grown over the years to accommodate a wide range of products. However, even with the spiraling increase in production, it has never compromised on Quality, which has always remained its mantra.

The company has put to operation three new manufacturing facilities covered under its Rs 1 billion expansion plans. The three facilities were a dedicated facility to manufacture Statins ( installed capacity of 40TPA) , a new dedicated facility for an Anti-Histamine drug ( installed capacity 27 TPA) and a New API facility at Samba, Jammu (installed capacity of 50TPA ) . All these facilities conform to USFDA standards and have been put to commercial production. The new facility at Jammu is situated in a tax free zone and shall be entitled to tax holiday for a period of ten years.

Strict Quality Control

Equipped with state-of-the-art quality testing equipment and well trained personnel, Ind-Swift maintains strict quality control, storage to delivery in accordance with GMP and ISO 9002. Quality of products meet the respective requirement of USP/BP/EP/JP etc., as per the international quality standards.

Manufacturing Facilities

  • 1,50,000 sq. ft. covered area
  • 5 Dedicated Blocks operating as per US FDA guidelines.
  • 132 Stainless Steel and Glass Lined Reaction Vessels with capacities ranging from 50 to 6000 liters. (Total Volume 245 kilo liters)
  • 3 Automated Fluidized Bed Coaters with capacity of manufacturing 3 MT of Granules per month.
  • cGMP Pilot Plant having 7 reaction vessels with capacities ranging from 250 to 1000 liters. (Total Volume 3.63 kilo liters)
  • Fully Automated Solvent Recovery System
  • Biological Waste Water Treatment Plant

Future plans

While development of new molecules will remain its core activity in the post patent era the Company will also focus on alternate and non-infringing routes for the drugs whose patent will expire in coming years.

To enter the regulated markets like USA, EU, Australia, and New Zealand, the company is focusing on getting its manufacturing plant approved by regulatory agencies like USFDA, TGA and MCA.

A new R&D Center with investment of $ 5 Million is already planned in Mohali with a focus to develop NCEs.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback